RxDoctor Payments Data

Christina Leber, APRN

Family · Harrodsburg, KYNPI 1336873983

Payments from drug & device makers

$764in general payments, 2019–2025

Across 42 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$393
  • Novo Nordisk$59
  • Lilly USA, LLC$48
  • Phathom Pharmaceuticals, Inc.$45
  • Exact Sciences$44
  • Pfizer$33
  • plus $142 from 7 others

What the payments were for

  • Food & beverage$764100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$764 in reported general payments places this provider in the 55th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$990
Medicare patients
47
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$72,009
JanuviaSitagliptin Phosphate48$54,411
EliquisApixaban30$30,346
FarxigaDapagliflozin Propanediol25$30,259
Victoza 3-PakLiraglutide11$14,784
JardianceEmpagliflozin16$14,271
Spiriva RespimatTiotropium Bromide12$10,341
Tresiba Flextouch U-100Insulin Degludec13$7,285
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,232
Albuterol Sulfate HfaAlbuterol Sulfate97$3,784
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,983
Duloxetine Hcl95$2,573
Atorvastatin Calcium249$2,104
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,966
Omeprazole240$1,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$59$72,00958 claims
PfizerEliquis$33$30,34630 claims
AstraZenecaFarxiga$31$30,25925 claims
Boehringer IngelheimJardiance, Spiriva Respimat$14$24,61328 claims
AbbVieSynthroid$393$1,65623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,374 family providers in Kentucky.

Other family in Harrodsburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →